Miaoxia He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miaoxia He has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Chun-Yan Xia
Department of Pathology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China
5 shared publicationsXia Sheng
Department of Pathology, Minhang Hospital, Fudan University, Shanghai 201199, China
5 shared publicationsHan Wang
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China; Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
4 shared publicationsHong-Zhen Chen
Department of Pathology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China
4 shared publications- Hui Dong
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China
4 shared publications - Wen-Ming Cong
Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease
Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical
- 28 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessChromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease
Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 163
Prognostic and therapeutic significance of microscopic tumor foci in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer lacking personalized pathological parameters. Microscopic tumor focus (MTF), a microscopic intrahepatic metastatic pattern, remains poorly characterized, with unclear prognostic and therapeutic relevance in cHCC-CCA. In this study, the detailed significance of MTF in cHCC-CCA was investigated. Methods: A multicenter study included 310 cHCC-CCA patients who underwent curative-intent hepatectomy. MTF was further graded by its number/distribution (MTF 0: absence of MTF; MTF 1: 1–5 proximal MTFs; MTF 2: >5 proximal MTFs/≥1 distal MTFs) and subclassified by its histology (HCC-type MTF; CCA-type MTF; HCC + CCA-type MTF). Results: MTF was detected in 48.1% (149/310) of patients (MTF 1: 43.2%, MTF 2: 4.8%; HCC-type MTF: 17.7%; CCA-type MTF: 20.6%; HCC + CCA type MTF: 9.7%). MTF positivity correlated with poorer recurrence-free survival (RFS) (median time: 0.23 and 0.89 years), early RFS, and overall survival (OS) (median time: 1.53 and 2.95 years, all P0.1 cm improved RFS, early RFS, and OS, while surgical margin had no effect on MTF-negative patients. Age, tumor diameter, microvascular invasion and perineural invasion independently predicted MTF (area under the curve =0.704); MTF histology was an independent prognostic factor for RFS, early RFS, and OS (all Harrell’s concordance index >0.7). Conclusions: This study standardized the definition of MTF and confirmed its prognostic value in cHCC-CCA. MTF stratification based on its number/distribution and histology enables more precise prognostic assessment. The presence of MTF could guide individualized selection of surgical margin.
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 163
Open AccessPrognostic and therapeutic significance of microscopic tumor foci in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer lacking personalized pathological parameters. Microscopic tumor focus (MTF), a microscopic intrahepatic metastatic pattern, remains poorly characterized, with unclear prognostic and therapeutic relevance in cHCC-CCA. In this study, the detailed significance of MTF in cHCC-CCA was investigated. Methods: A multicenter study included 310 cHCC-CCA patients who underwent curative-intent hepatectomy. MTF was further graded by its number/distribution (MTF 0: absence of MTF; MTF 1: 1–5 proximal MTFs; MTF 2: >5 proximal MTFs/≥1 distal MTFs) and subclassified by its histology (HCC-type MTF; CCA-type MTF; HCC + CCA-type MTF). Results: MTF was detected in 48.1% (149/310) of patients (MTF 1: 43.2%, MTF 2: 4.8%; HCC-type MTF: 17.7%; CCA-type MTF: 20.6%; HCC + CCA type MTF: 9.7%). MTF positivity correlated with poorer recurrence-free survival (RFS) (median time: 0.23 and 0.89 years), early RFS, and overall survival (OS) (median time: 1.53 and 2.95 years, all P0.1 cm improved RFS, early RFS, and OS, while surgical margin had no effect on MTF-negative patients. Age, tumor diameter, microvascular invasion and perineural invasion independently predicted MTF (area under the curve =0.704); MTF histology was an independent prognostic factor for RFS, early RFS, and OS (all Harrell’s concordance index >0.7). Conclusions: This study standardized the definition of MTF and confirmed its prognostic value in cHCC-CCA. MTF stratification based on its number/distribution and histology enables more precise prognostic assessment. The presence of MTF could guide individualized selection of surgical margin.
- Open Access
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1788462
Multi-omics analysis identifies CLDN10 as a B-cell-associated prognostic biomarker in HPV-negative head and neck squamous cell carcinoma
Background: The prognosis of head and neck squamous cell carcinoma (HNSC) is poor, and new biomarkers are urgently needed. Claudin 10 (CLDN10) plays an important role in various tumors, but its function in HNSC remains unclear. Methods: Through bioinformatics analysis and experimental verification, the expression, prognostic value, and immunological correlation of CLDN10 in HNSC were systematically evaluated. Results: CLDN10 is downregulated in human papillomavirus negative HNSC, and its low expression is significantly associated with a decreased overall survival of patients, and it is an independent prognostic factor. Functional enrichment analysis shows that CLDN10 and its co-expressed genes are mainly enriched in B-cell-related immune pathways. Further analysis indicates that the expression level of CLDN10 is strongly correlated with the degree of B-cell infiltration in HNSC. Conclusion: The downregulation of CLDN10 is associated with poor prognosis in HNSC, especially in HPV-negative patients, and it has significant prognostic value. Its mechanism of action may involve the regulation of B-cell-mediated tumor immune response, providing potential targets for immunotherapy and prognosis assessment of HNSC.
- 3 March 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1788462
Open AccessMulti-omics analysis identifies CLDN10 as a B-cell-associated prognostic biomarker in HPV-negative head and neck squamous cell carcinoma
Background: The prognosis of head and neck squamous cell carcinoma (HNSC) is poor, and new biomarkers are urgently needed. Claudin 10 (CLDN10) plays an important role in various tumors, but its function in HNSC remains unclear. Methods: Through bioinformatics analysis and experimental verification, the expression, prognostic value, and immunological correlation of CLDN10 in HNSC were systematically evaluated. Results: CLDN10 is downregulated in human papillomavirus negative HNSC, and its low expression is significantly associated with a decreased overall survival of patients, and it is an independent prognostic factor. Functional enrichment analysis shows that CLDN10 and its co-expressed genes are mainly enriched in B-cell-related immune pathways. Further analysis indicates that the expression level of CLDN10 is strongly correlated with the degree of B-cell infiltration in HNSC. Conclusion: The downregulation of CLDN10 is associated with poor prognosis in HNSC, especially in HPV-negative patients, and it has significant prognostic value. Its mechanism of action may involve the regulation of B-cell-mediated tumor immune response, providing potential targets for immunotherapy and prognosis assessment of HNSC.
- 26 February 2026
- Published by Elsevier in Pattern Recognition Letters
- Vol. 203, 57-63
ZA-Net: A universal zero-annotation nuclei segmentation network for pathology images via vision-language pre-trained model
- 26 February 2026
- Published by Elsevier in Pattern Recognition Letters
- Vol. 203, 57-63
ZA-Net: A universal zero-annotation nuclei segmentation network for pathology images via vision-language pre-trained model
- Open Access
- 24 January 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma
Meningiomas are the most common primary intracranial tumor in adults and systemic therapy is urgently needed for high-grade fatal tumors and those cannot b
- 24 January 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessDeficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma
Meningiomas are the most common primary intracranial tumor in adults and systemic therapy is urgently needed for high-grade fatal tumors and those cannot b
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Genes & Diseases
Epigenetic landscape of angioimmunoblastic T-cell lymphoma: From molecular pathogenesis to precision therapeutics
- 1 January 2026
- Published by KEAI Publishing in Genes & Diseases
Open AccessEpigenetic landscape of angioimmunoblastic T-cell lymphoma: From molecular pathogenesis to precision therapeutics
- 17 December 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 278, 156335
Deciphering the significance of tumor necrosis and developing a grading system in combined hepatocellular-cholangiocarcinoma: A multicenter pathological study
- 17 December 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 278, 156335
Deciphering the significance of tumor necrosis and developing a grading system in combined hepatocellular-cholangiocarcinoma: A multicenter pathological study
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 3011-3027
A Grading System of Intratumoral Tertiary Lymphoid Structure for Combined Hepatocellular-Cholangiocarcinoma: A Multicenter Pathological Study
Tertiary lymphoid structure (TLS) has been well-established across multiple tumor types for predicting efficacy of immunotherapy and prognostic evaluation. However, its role in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) remains unclear. Refinement of TLS pathological assessment could potentially optimize postoperative management in these patients. This study aimed to develop a practical histopathological grading system of intratumoral TLS to improve prognostic stratification of cHCC-CCA patients. A cohort of 310 cHCC-CCA patients undergoing hepatectomy with curative intent was analyzed. Three pathologists re-evaluated pathological slides to establish a four-tier TLS grading system: TLS 0 (absent), TLS 1 (immature TLS only), TLS 2a [single mature TLS (mTLS)], and TLS 2b (multiple mTLS). Associations with recurrence-free survival (RFS), overall survival (OS), early RFS (≤1 year), late RFS (>1 year), and recurrence patterns were assessed. Predictive factors for TLS were also investigated. Patients were stratified into TLS 0 (29.4%), TLS 1 (51.6%), TLS 2a (6.8%), and TLS 2b (12.3%). Survival outcomes significantly correlated with TLS presence and maturation. Median RFS increased stepwise: 0.24 years (TLS 0), 0.49 years (TLS 1), 1.13 years (TLS 2a), and 1.16 years (TLS 2b) (P<0.001). Median OS also improved progressively: 1.32 years (TLS 0), 2.20 years (TLS 1), 3.24 years (TLS 2a), and 10.04 years (TLS 2b) (P<0.001). TLS presence was associated with increased extrahepatic recurrence. The TLS grading system emerged as an independent prognostic factor for RFS, OS, and early RFS. Smaller tumor diameter was the sole significant predictive factor for both TLS and mTLS. This novel TLS grading system effectively stratifies prognosis in cHCC-CCA, with increasing intratumoral mTLS indicating better outcomes. This practical method can be integrated into routine pathological reporting to aid clinical decision-making.
- 1 December 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 3011-3027
Open AccessA Grading System of Intratumoral Tertiary Lymphoid Structure for Combined Hepatocellular-Cholangiocarcinoma: A Multicenter Pathological Study
Tertiary lymphoid structure (TLS) has been well-established across multiple tumor types for predicting efficacy of immunotherapy and prognostic evaluation. However, its role in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) remains unclear. Refinement of TLS pathological assessment could potentially optimize postoperative management in these patients. This study aimed to develop a practical histopathological grading system of intratumoral TLS to improve prognostic stratification of cHCC-CCA patients. A cohort of 310 cHCC-CCA patients undergoing hepatectomy with curative intent was analyzed. Three pathologists re-evaluated pathological slides to establish a four-tier TLS grading system: TLS 0 (absent), TLS 1 (immature TLS only), TLS 2a [single mature TLS (mTLS)], and TLS 2b (multiple mTLS). Associations with recurrence-free survival (RFS), overall survival (OS), early RFS (≤1 year), late RFS (>1 year), and recurrence patterns were assessed. Predictive factors for TLS were also investigated. Patients were stratified into TLS 0 (29.4%), TLS 1 (51.6%), TLS 2a (6.8%), and TLS 2b (12.3%). Survival outcomes significantly correlated with TLS presence and maturation. Median RFS increased stepwise: 0.24 years (TLS 0), 0.49 years (TLS 1), 1.13 years (TLS 2a), and 1.16 years (TLS 2b) (P<0.001). Median OS also improved progressively: 1.32 years (TLS 0), 2.20 years (TLS 1), 3.24 years (TLS 2a), and 10.04 years (TLS 2b) (P<0.001). TLS presence was associated with increased extrahepatic recurrence. The TLS grading system emerged as an independent prognostic factor for RFS, OS, and early RFS. Smaller tumor diameter was the sole significant predictive factor for both TLS and mTLS. This novel TLS grading system effectively stratifies prognosis in cHCC-CCA, with increasing intratumoral mTLS indicating better outcomes. This practical method can be integrated into routine pathological reporting to aid clinical decision-making.
- Open Access
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1653534
Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection
Introduction: Since the release of the World Health Organization (WHO) Classification of Tumours-Digestive System Tumours in 2019, the pathology of intrahepatic cholangiocarcinoma (iCCA) has entered an era of integrated diagnosis, encompassing gross classification, histological subtyping, as well as drug molecular target screening. Substantial evidence indicates that the histological subtypes of iCCA are significantly associated with the detection frequency of molecular targets relevant to the targeted therapy and immunotherapy. Through rational immunohistochemistry profiling, patients with iCCA can be precisely diagnosed and individually managed.Methods: A thorough literature search was conducted using terms pertinent to the pathological diagnosis, histological subtyping, targeted therapy, and immunotherapy of iCCA. The content related to immunohistochemistry was summarized.Results: In the first part, we summarize the immunohistochemical markers for the histological subtype of iCCA (e.g., large duct type iCCA, small duct type iCCA), with a particular emphasis on their percentage of positive cases, expression location, and association with prognosis. Subsequently, a summary of the immunohistochemical markers for targeted therapy and immunotherapy of iCCA is performed, focusing on the consistency between immunohistochemistry and molecular detection, optimal clone, and prognostic significance.Conclusions: This review summarizes the critical role of immunohistochemistry in the pathological diagnosis of iCCA. It is noted that any diagnosis must be made by integrating comprehensive information. A pathological diagnosis merely based on immunohistochemical results is unreasonable. The development of subtype-specific and drug-targeted antibodies holds promise for refining iCCA precise diagnosis and therapeutic stratification.
- 6 October 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1653534
Open AccessImmunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection
Introduction: Since the release of the World Health Organization (WHO) Classification of Tumours-Digestive System Tumours in 2019, the pathology of intrahepatic cholangiocarcinoma (iCCA) has entered an era of integrated diagnosis, encompassing gross classification, histological subtyping, as well as drug molecular target screening. Substantial evidence indicates that the histological subtypes of iCCA are significantly associated with the detection frequency of molecular targets relevant to the targeted therapy and immunotherapy. Through rational immunohistochemistry profiling, patients with iCCA can be precisely diagnosed and individually managed.Methods: A thorough literature search was conducted using terms pertinent to the pathological diagnosis, histological subtyping, targeted therapy, and immunotherapy of iCCA. The content related to immunohistochemistry was summarized.Results: In the first part, we summarize the immunohistochemical markers for the histological subtype of iCCA (e.g., large duct type iCCA, small duct type iCCA), with a particular emphasis on their percentage of positive cases, expression location, and association with prognosis. Subsequently, a summary of the immunohistochemical markers for targeted therapy and immunotherapy of iCCA is performed, focusing on the consistency between immunohistochemistry and molecular detection, optimal clone, and prognostic significance.Conclusions: This review summarizes the critical role of immunohistochemistry in the pathological diagnosis of iCCA. It is noted that any diagnosis must be made by integrating comprehensive information. A pathological diagnosis merely based on immunohistochemical results is unreasonable. The development of subtype-specific and drug-targeted antibodies holds promise for refining iCCA precise diagnosis and therapeutic stratification.